SLEEMAN, MARK W.,史利门 马克,史利門 馬克,GUSAROVA, VIKTORIA,格沙罗凡 维多利亚,格沙羅凡 維多利亞,MURPHY, ANDREW J.,墨菲 安德鲁,墨菲 安德魯,史利门 马克,史利門 馬克,格沙罗凡 维多利亚,格沙羅凡 維多利亞,墨菲 安德鲁,墨菲 安德魯
申请号：
TW106123582
公开号：
TW201815822A
申请日:
2012.06.15
申请国别(地区):
TW
年份:
2018
代理人:
摘要：
A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hANGPTL3) is provided. The human anti-hANGPTL3 antibodies are useful in treating diseases or disorders associated with ANGPTL3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL3 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases； acute pancreatitis； nonalcoholic steatohepatitis (NASH)； diabetes； obesity； andthe like.提供一種專一性結合及抑制或干擾至少一種人類類血管生成素蛋白3(hANGPTL3)活性之全人類抗體或人類抗體之抗原結合片段。人類抗-hANGPTL3抗體可用於治療於有關的疾病或病症，例如高脂血症、高脂蛋白血症和血脂異常，包括高三酸甘油酯、高膽固醇血症、乳糜微粒血症等等。再者，抗-hANGPTL3抗體可投予有此需要之對象用以預防或治療脂質代謝異常為一風險因子之疾病或病症。此疾病或病症包括心血管疾病，例如動脈硬化和冠狀動脈疾病；急性胰臟癌；非酒精性脂性肝炎(NASH)；糖尿病；及肥胖症；及類似病症。
